Supernus Pharmaceuticals, Inc. Senior Vice-President and CFO Timothy C. Dec filed a Form 4 on November 2, 2026, disclosing the acquisition of 70,000 restricted stock units on October 30, 2026.

Key Highlights

  • Reporting person: Timothy C. Dec, Senior Vice-President and CFO of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
  • Award granted: 70,000 restricted stock units (RSUs) acquired on October 30, 2026, at a price of $0
  • Post-transaction holdings: 70,000 derivative securities beneficially owned following the reported transaction, held directly
  • Vesting trigger: 50% of RSUs vest upon the closing of the merger-of-equals transaction between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc.
  • Remaining vesting schedule: 15% vest at one-year post-closing, 15% at two-year post-closing, and 20% at three-year post-closing
  • Settlement: RSUs are settled in common stock upon vesting

Dec's RSU Grant Details and Merger-Linked Vesting Terms

According to the filing, Timothy C. Dec, in his capacity as Senior Vice-President and CFO of Supernus Pharmaceuticals, Inc., received 70,000 restricted stock units on October 30, 2026. The transaction was coded as an acquisition (code "A") with a price of $0, and the RSUs are classified as derivative securities that will be settled in shares of Supernus common stock upon vesting.

The filing discloses that the RSUs vest in four installments, with the schedule directly tied to a pending merger. Specifically, the filing states that these RSUs "are settled in common stock upon vesting, which occurs in four installments. 50% of the RSUs vest upon the closing of the merger-of-equals transaction between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (the 'Closing'). 15% of the RSUs vest upon the one-year anniversary of the Closing. 15% of the RSUs vest upon the two-year anniversary of the Closing. 20% of the RSUs vest upon the three-year anniversary of the Closing."

Following the reported transaction, the filing indicates that Dec beneficially owns 70,000 derivative securities directly. The Form 4 was signed by Timothy C. Dec and filed on November 2, 2026. No Table I non-derivative securities transactions were reported in this filing.

What Was Disclosed

Supernus Pharmaceuticals CFO Timothy C. Dec disclosed the acquisition of 70,000 RSUs on October 30, 2026, with vesting contingent on the closing of and subsequent anniversaries following a stated merger-of-equals transaction with Indivior Pharmaceuticals, Inc.